Catalent and BrainStorm Cell Therapeutics Inc announced an agreement for the manufacture of NurOwn®, BrainStorm’s autologous cellular therapy being investigated for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neuron disease.

Catalent today announced that its experts will present at the upcoming American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 event, which takes place virtually from Oct. 26 – Nov. 5, 2020.

Catalent today announced the launch of OptiGel® DR technology for the formulation and manufacture of delayed/enteric release softgels. The technology allows softgel capsules to be formed by combining pectin, a naturally derived polysaccharide, with gelatin, eliminating the need for a separate capsule coating step.

Catalent today announced that Jesse Trekker, Ph.D., Business Director, Strategic Partnerships, Catalent Cell & Gene Therapy, will present at the Allogeneic Cell Therapies Summit, which will take place virtually on 26 – 28 October, 2020.

Catalent today announced that it will be participating in several roundtables alongside other leading industry experts at the CPhI Festival of Pharma, which is taking place virtually between Oct. 5 – 16, 2020.

Catalent today announced the launch of its new OneXpress™ service for the integrated development, scale up and manufacturing of new oral solid dosage forms.

Catalent’s clinical supply site in Bathgate has won Scottish Engineering’s ‘Vice President Award 2020,’ recognising its continuous improvement programme in core values including “patient first, customer dedication, people, innovation, integrity and excellence.”

Catalent today welcomed the news from Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule charged sodium channel blockers, that its first patient has been dosed with NOC-100, an inhaled formula of its NTX-1175 small molecule candidate.

Catalent today announced that it has acquired a new manufacturing facility in Bloomington, Indiana, to create a North American center of excellence for early-phase clinical biologics formulation development and drug product fill/finish services.